AGENDA: DUR BOARD MEETING
Colorado Medicaid Drug Utilization Review (DUR) Board
Department of Health Care Policy and Financing

Skaggs School of Pharmacy and Pharmaceutical Sciences Building
12850 East Montview Blvd, Aurora CO 80045
Seminar Room- Room 1000; First floor
Parking available in the Henderson/Visitor Parking Garage

August 14th, 2018
6:00 p.m. – 9:00 p.m. Open Session

DUR BOARD MEMBERS and CO-DUR MEMBERS

<table>
<thead>
<tr>
<th>DUR Board Members</th>
<th>CO-DUR Team</th>
</tr>
</thead>
<tbody>
<tr>
<td>LeWayne Garrison, PharmD</td>
<td>Cathy Traugott, RPh, JD (HCPF)</td>
</tr>
<tr>
<td>Sheila Botts, PharmD</td>
<td>Jeffrey Taylor, PharmD (HCPF)</td>
</tr>
<tr>
<td>Alex Reish, DO</td>
<td>Robert L Page, PharmD, MSPH (CO DUR)</td>
</tr>
<tr>
<td>Allison Blackmer, PharmD</td>
<td>Brandon Utter, PharmD (CO DUR)</td>
</tr>
<tr>
<td>Alison Shmerling, MD</td>
<td>Jon Campbell, PhD (CO DUR)</td>
</tr>
<tr>
<td>Michael Noonan, DO</td>
<td>Garth Wright, MPH (CO DUR)</td>
</tr>
<tr>
<td>Mary Wilkerson, MD</td>
<td>Gina Moore, PharmD, MBA (CO DUR)</td>
</tr>
<tr>
<td>Liza Wilson Claus, PharmD</td>
<td>Corinne Copeland (Industry Representative)</td>
</tr>
</tbody>
</table>

1. Roll Call / Introductions / Chair and Vice Chair Election

2. Approval of the minutes from the May 15th, 2018 meeting

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.

www.colorado.gov/hcpf
3. Rules

- Agenda items must be approved in advance, including requests to present information. Please contact the DUR Pharmacist, Jeff Taylor, at Jeffrey.Taylor@state.co.us with questions.
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours before the meeting.

4. Open Session

A. Unfinished Business and General Orders

- Department Update
- FDA updates

Updates on Proposed PDL Criteria from Last Meeting: (not scheduled for public testimony or board review)

- Acne agents (New PDL Class)
- Angiotensin Modulators and Angiotensin Modulator Combinations
  - ACEis and ACEi Combos (New PDL Class)
  - ARBs and ARB Combos
  - Renin Inhibitors and Combos
- Fibromyalgia and Neuropathic Pain Agents
- Opioids – Short Acting (New PDL Class)
- Opioids – Long Acting
- Respiratory Inhalants
  - Anticholinergics and Anticholinergic Combos
  - Beta$_2$ Agonists (short-acting)
  - Beta$_2$ Agonists (long-acting)
  - Inhaled Corticosteroids and Combinations
- Testosterone products
- Antihistamines, Newer-Generation and Decongestant Combinations
- Skeletal Muscle Relaxants
- Topical Immunomodulators

Updates on Proposed Criteria/Additional Items from Last Meeting: (not scheduled for public testimony or board review)

- Steglatro® (ertugliflozin)
- Xifaxin® (rifaximin)
- Ferriprox® (deferiprone)
- Jadenu® (deferasiropx)
- Exjade® (deferasiropx)
- Symdeko® (tezacaftor/ivacaftor – and ivacaftor)
Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.

www.colorado.gov/hcpf

- Makena® autoinjector (hydroxyprogesterone)

B. **New Business** (open for public testimony and board review)

**Proposed Criteria for current PDL:**

- Anticoagulants – Oral
- Anticonvulsants (new PDL class)
- Bone Resorption Suppression and Related Agents
- Contraceptives, Oral
- Diabetes Management Classes
  - Biguanides
  - Hypoglycemic Combinations
  - Meglitinides
  - DPP-4 Inhibitors
  - GLP-1 Analogues
  - SGLT-2 Inhibitors
  - Amylin Agonists
  - Thiazolidinediones
- Erythropoiesis Stimulating agents
- Hereditary Angioedema (HAE) Agents (new PDL class)
- GI Motility Agents
- Overactive Bladder agents
- Prenatal Vitamins (new PDL class)
- Stimulants and other ADHD agents
- Ophthalmic Immunomodulators
- Colony Stimulating Factors

**Other Proposed Criteria/Additional Items:**

- Syprine (triethylenetetramine)
- Lucemyra (lofexidine)
- Dificid (fidaxomycin)
- Aimovig (erenumab-aooe)
- HP Acthar (corticotropin)
- Ocrevus (ocrelizumab)
- Tysabri (natalizumab)

**Further DUR Updates:**

- Retrospective DUR updates
- Quarterly module summary
- Quarterly Drug Utilization Reports
5. Adjourn

- Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at 303- 866-3105 or jeffrey.taylor@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.